NOW A POWERFUL NEW ALTERNATIVE FOR GENITAL HERPES



Based on "The Kiss," Auguste Rodin, 1886.

'Famvir' 250 mg Tablets
'Famvir' 125 mg Tablets
famciclovir
Prescribing Information
Presentations 'Famvir Tiltab' 250 mg Tablets, PL 10592/0035, each containing 250 mg famciclovir. 21 tablets: £107.35, 15 tablets £76.68, 210 tablets: £1073.50. 'Famvir Tiltab' 125 mg Tablets, PL 10592/0055, each containing 125 mg famciclovir. 10 tablets: £25.56.
Uses Treatment of herpes zoster (shingles) infections and acute genital herpes infections. Famciclovir is the oral form of penciclovir, converted in the body to this active antiviral moiety.
Dosage and administration *Herpes zoster (shingles) infection Adults:* One 250 mg tablet t.d.s. for 7 days. Treatment should be initiated as early as possible in the course of the disease, promptly after diagnosis. *First-episode genital herpes infections Adults:* One 250 mg tablet three times daily for 5 days. Initiation of treatment is recommended as soon as possible after onset of lesions. *Acute recurrent genital herpes infections Adults:* One 125 mg tablet twice daily for 5 days. Initiation of treatment is recommended during the prodromal period or as soon as possible after onset of lesions. *Elderly:* As for adults unless renal function impaired. *Renally impaired and renally impaired on haemodialysis:* Reduced clearance of penciclovir related to reduced function; see Data Sheet for dosage modification. *Hepatically impaired:* No dosage modification required in well compensated hepatic impairment. *Children:* Data currently insufficient on safety and efficacy.
Contra-indication Known hypersensitivity to famciclovir.
Precautions Care in impaired renal function (see Data Sheet).
Drug interactions No clinically significant pharmacokinetic interactions identified. Probenecid and other drugs affecting the kidney could affect plasma levels of penciclovir.
Use in pregnancy and lactation Not to be used during pregnancy or lactation unless benefits outweigh risk. Oral penciclovir excreted in breast milk of lactating rats.
Adverse reactions Well tolerated in human studies. Generally mild or moderate headache and nausea reported in clinical trials and occurring at similar incidence to placebo.
Overdosage No acute overdosage reported. Symptomatic and supportive therapy as appropriate.
Legal category POM. 15.3.95.

SB **SmithKline Beecham** *Pharmaceuticals*
Healthy Alliance
partnership beyond prescription

Welwyn Garden City, Hertfordshire AL7 1EY

0395 FM:AD/5/120/GM

FAMVIR
famciclovir

AN IMPORTANT INNOVATION FROM SMITHKLINE BEECHAM ANTIVIRAL RESEARCH



Current Opinion in INFECTIOUS DISEASES

Subscribe now and stay up-to-date

KEEP UP-TO-DATE WITH CURRENT OPINION

- Every year it is the most reliable source of information in the field.
- Every year the whole field is covered in 6 bi-monthly issues, broken down into 13 subjects.
- Every year within each subject, all the latest developments, expert comment and opinion, and recommended reading are featured.
- Every year **Current Opinion in Infectious Diseases** is the only reference you need to keep fully informed.

PRICES FOR ANNUAL SUBSCRIPTION

£79.95 - $134.95 Personal

£169.95 - $269.95 Institutional

£45 - $55 Pre-reg doctors/Residents

Postage: £10 UK £15.75 Eur $11 N Am $37 S Am £25 RoW

EDITORS

RG Finch & VT Andriole

1995 SECTIONS AND EDITORS

February
SEXUALLY TRANSMITTED DISEASES AND URINARY TRACT INFECTIONS *AR Ronald*
HIV INFECTION AND AIDS *JP Phair*

April
RESPIRATORY INFECTIONS *M Woodhead*
GENERALIZED INFECTIONS *AL Bisno*

June
PATHOGENESIS AND IMMUNE RESPONSE *DL Stevens*
PEDIATRIC AND NEONATAL INFECTIONS *M Radetsky*

August
INFECTIONS OF THE IMMUNOCOMPROMISED HOST *HG Prentice & CC Kibbler*
NOSOCOMIAL AND HOSPITAL-RELATED INFECTIONS *PJ Sanderson*
SKIN AND SOFT-TISSUE INFECTIONS *S Ash*

October
TROPICAL AND TRAVEL-ASSOCIATED DISEASES *DR Hill*
GASTROINTESTINAL INFECTIONS *R Fekety*

December
ANTIMICROBIAL AGENTS: BACTERIAL/FUNGAL *GP Bodey*
ANTIMICROBIAL AGENTS: VIRAL/PARASITIC *PL Chiodini & RJ Whitley*

TO SUBSCRIBE IN N & S AMERICA CONTACT:
Current Science Ltd, Suite 700, 400 Market Street,
Philadelphia, PA 19106, USA.
Tel: 215-574-2210, or Toll Free: 800-552-5866 (US only)
Fax: 215-574-3533

IN THE REST OF WORLD:
Current Science Ltd, Middlesex House,
34-42 Cleveland Street, London W1P 6LB, UK.
Tel: +44 (0) 171 323 0323, or Freephone: 0800 212530 (UK only)
Fax: +44 (0) 171 636 6911

How to do it even better!

The highly popular *How To Do It* series is a collection of expert advice on an enormous range of topics that doctors need to know about that are not necessarily covered in formal training.

All three volumes have now been completely updated, with new chapters, and a user friendly format where subjects are grouped into themes. Whether you want to chair a committee, improve your counselling skills with cancer patients, or even survive a formal dinner, your questions will be answered in these entertaining and practical guides.

A must for all doctors, from students through to the retired.



How to Do It Volume 1
● Management ● Employment ● Counselling
ISBN 0 7279 0848 0 272 pages April 1995
UK £12.95; Overseas £15.00
(BMA members £11.95; £14.00)



How to Do It Volume 2
● Examinations ● Academia ● Research and Communication
ISBN 0 7279 0895 2 240 pages April 1995
UK £12.95; Overseas £15.00
(BMA members £11.95; £14.00)



How to Do It Volume 3
● Writing ● Publishing and Publicity ● Something Different
ISBN 0 7279 0896 0 264 pages April 1995
UK £12.95; Overseas £15.00
(BMA members £11.95; £14.00)

Purchase the complete set at a reduced price!

ISBN 0 7279 0906 1 UK £34.95; Overseas £39.00 (BMA members £31.95; £36.00)



BMJ Publishing Group

Order Form

Available from: **BMJ Publishing Group, P.O. Box 295, London WC1H 9TE, (Tel: 0171 383 6185/6245), medical booksellers or the BMJ bookshop in BMA House**

Please send me _____ copy/ies of **HOW TO DO IT VOLUME 1**

Please send me _____ copy/ies of **HOW TO DO IT VOLUME 2**

Please send me _____ copy/ies of **HOW TO DO IT VOLUME 3**

Please send me _____ **COMPLETE SET/S OF HOW TO DO IT**

Please send me _____ copy/ies of **HOW TO WRITE A PAPER**

BMA Membership No. _____

Name _____
(Print Clearly)

Address _____

_____

_____ **Postcode** _____

Cheque enclosed (made payable to British Medical Journal) £ _____

Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Card No. _____ **Exp** _____

Signature _____

❑ Please send me a BMJ PUBLISHING GROUP CATALOGUE

On reflection, no other treatment looks so convenient

Many women with genital warts would welcome the convenience and dignity of treating themselves at home.

New Warticon Fem makes self-treatment practical by the simple inclusion of a mirror in every pack.

Proven to be effective[1] and well tolerated[2] when used in this way, Warticon Fem is now a clear first choice treatment.

NEW

Warticon®
fem
Podophyllotoxin 0.5%w/v

Clearly simple enough for self-application in female genital warts

Perstorp Pharma Further information is available from: Perstorp Pharma Ltd, Intec 2, Wade Road, Basingstoke, Hants RG24 8NE. Tel: 0256 477868.

REFERENCES 1. Baker D. A, et al. Obstet Gynecol 1990; 76: 656-9. 2. Kinghorn G. R, et al. 1993; In press.